A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor

Abstract excerpt

Rheumatology key message In patients with refractory catastrophic APS, eculizumab may be a useful and cost-effective alternative. Sir, Catastrophic anti-phospholipid syndrome (CAPS) is the most severe and rare form of APS, presenting with acute multiple-organ involvement, small-vessel thrombosis and visceral damage [1]. We present a case of CAPS that was refractory to conventional therapy. For the sake of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Peripheral Neuropathies and Disorders
• Share to Platelet Disorders and Treatments
• Share to Systemic Lupus Erythematosus Research